Factors Affecting Dose Selection
|
|
- Chastity McCormick
- 6 years ago
- Views:
Transcription
1 Long Acting Injectables for HIV-PrEP Factors Affecting Dose Selection June 14 to 16, 2017 Mark Milad Milad Pharmaceutical Consulting, LLC Consultant to the Bill and Melinda Gates Foundation
2 Outline Challenges in global health Dose selection for prevention studies Impact of variability on dose selection Engineering drug forgiveness Tools to simulate long term effectiveness 2
3 Bill and Melinda Gates Foundation 3
4 Mismatch and Need for Simplification HIV Prevalence Available Physicians Source: 4
5 New Challenges with Products for Population in Sub-Saharan Africa Old Challenges (ICHE5) Genetic Polymorphism of Drug Metabolism and Disease Genetic Disease Demographics Race, Sex, Height, Weight, Age Liver, Kidney, Cardiovascular Disease Smoking, Alcohol Use Food Habits Regulatory Practice Drug Compliance Education, Therapeutic Approach New Challenges Significant Barriers to Adherence Access to Medical Care Travel Distance and Method of Travel Supply Chain Inconsistent Cost Stigma and Need for Privacy Lack of Agency Sex Workers Conceal Medication Use Laws Criminalizing People Who Expose Others to HIV Education Material Differences Western Reference Points Differ from Those in Africa (i.e. Few Stop Lights in Villages) Fewer Health Care Workers (Physician and Nurses) For Long Acting Injectable Skin Thickness 5
6 Development of HIV PrEP is at a Very Early Stage Compared to Contraceptives Contracept Worldwide 85 M unintended pregnancies (2012) Semi-Permanent or Permanent Sterilization male or female IUDs Implant Taken Every 1-3 months OC Pill Vaginal Ring Taken Daily OC Pill As Needed Diaphragm Condoms male and female Spermicide Non Pharmacologic HIV PrEP Worldwide 2.1 M newly infected with HIV (2015) In-Progress Long acting Injectables Implant Vaginal Ring Taken Daily FTC/TDF As Needed Condoms male and female 6
7 Concept Target Product Profiles Contraceptives Longer- Acting 6 to 12 months Forgiveness designed into new product 1 month for 6mo-contraceptive Product Consistent and reliable return to fertility Self-Injection Sub-cutaneous (SC) preferred to Intramuscular (IM) Lower side effects HIV PrEP Long-acting Desired duration 6 to 12 mo Preference for SC dosing Injection volume of 2mL or less Lower dose (i.e. 300 mg or less) Gaps in TPP Timer with indicator Quantify result of missed dose Multiple injection location 7
8 Dose Selection for Prevention Studies Contraception and HIV PrEP have dichotomous and permanent outcomes Require very high rates of efficacy Based on target blood concentrations at trough Near all subjects to remain above a target concentration In a one-dose-fits-all environment, vast majority of subjects will be overdosed Increased variability therefore increases total dose Target Mean 8
9 PK/PD Simulator for Depo Medroxy-Progesterone Acetate Long Acting Injectable Pharmacokinetic Input Simulated PK Output Pharmacodynamic Input Simulated Endpoint Output (i.e. Ovulation) 9
10 Concentration % Return to Ovulation Simulation of Increased PK Variability Showing Earlier Return to Ovulation for 5 th Percentile of Women CV in PK Conc 40% 70% Time for 5 th Percentile Return to Ovulation 4.7 mo 4 mo Target % Suppressed Threshold Value Time, Months Time, Months 10
11 Contraceptive Efficacy Gap Between Perfect and Typical Use Derived from B Hatcher 2014 Typical use: how well the method works when real people in real life use it. Perfect use: how well the method works when it's used in a clinical trial. 11
12 Drug Forgiveness Forgiveness is defined as the difference between the medication s post-dose duration of beneficial action and the prescribed dosing interval. Relates to the number of doses that can be skipped without causing detectable disease relapse. Definition pertains to daily administration not to long acting where dosed every 3 or 6 months for protection. Feature of the drug or dosage form. Challenge: To engineer product with drug forgiveness. Dartois V
13 Engineering Drug Forgiveness Few of the Variables Choice of API Injection Site Formulation Release Rate Dose Selection Measure Forgiveness PK Outcomes 13
14 HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women Women (18 to 45 years old) at risk for acquiring HIV N = 3,200 women in Sub-Saharan Africa Treatment Run In Injection Phase (1yr) Follow UP A Daily oral CAB CAB LA 600 mg Q8 Week, extra dose at Week 4 Open-label daily TDF/FTC B Daily TDF/FTC Daily TDF/FTC Open-label daily TDF/FTC 14
15 Measure of Forgiveness Based on PK Predicted % of Female Subjects Achieving Trough Concentrations > 4xPA-IC90 Targets Following Delays in CAB LA Dosing Time of Delay Injection Injection 2 (week 4) Injection 3 (week 12) Injection 4 (week 20) 0 (Right On Time) +1 Week +2 Week +3 Week +4 Week HPTN 084 Protocol V1.0 2 March Provided by Susan Ford, Kelong Han GlaxoSmithKline and Parul Patel, Viiv 15
16 HIV PrEP Simulator for LA CAB Population PK Parameters Input Subject Adherence Demographics Dose and Transmission Rate (without drug) Exposure Regimen (e.g mg LD, 800 mg Q12w PK Model based on data presented in 2014 (Data from Ford et al. 2014, Model/Simulator built in Microsoft Excel by Bill Poland, Centara Inc Target Trough Plasma Conc (e.g. 4 PA IC90 Frequency Output Individual and Population Conc Time Profiles Probability of Transmission Over Time 16
17 Simulator for LA CAB Example Individual Subject Profile Population: 1:1 ratio sex Dose: LD 1600 mg, 800 mg Q12W (old regimen) Adherence: SD 2.38 Weeks Poor adherence CAB conc drop below threshold potential exposure/transmission 17
18 Simulator for LA CAB Example Population Profile Population: 1:1 ratio sex, BMI is median value Dose: LD 1600 mg, 800 mg Q12W (old regimen) Adherence: SD = 2.38 Weeks 95% Mean 50% 5% Although individuals subject concentrations drop below threshold, the population 5th percentile may not drop below threshold 18
19 Impact of Poor Adherence on Portion of Subjects Infected (example simulator for LA CAB) If 25 % of doses are late by 1 yr 5 yr 10 yr 20 yr 40 yr 0 days (on time) 0.4% 2% 3% 4% 6% 10 days 0.6% 3% 4% 6% 8% 35 days 2% 7% 11% 15% 19% Input: Sex 1:1, Dose: LD 1600 mg, 800 mg Q12W (old regimen), Transmission rate: 0.04/exposure, 2 exposures per week, no early dosing (<tau). Example model based simulation with assumptions, dose, regimen and PK parameters bases on older data. 19
20 Summary Respond to challenges of dose selection for prevention drugs Consider impact of new sources of variability with long acting injectables in global health Engineer drugs with forgiveness Modeling and simulation to help dose selection and put adherence and forgiveness in context 20
21 Contributors Bill Poland, Certara Inc, Simulations Susan Ford, GSK insight into HPTN-084 Parul Patel, Viiv insight into HPTN
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationNext Generation PrEP? Injectable & Implantable ARVs
Next Generation PrEP? Injectable & Implantable ARVs Craig W. Hendrix, MD Wellcome Professor & Director, Clinical Pharmacology Johns Hopkins University Objectives Describe alternative formulations to improve
More informationInjectable Antiretrovirals The Promise and the Peril. Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015
Injectable Antiretrovirals The Promise and the Peril Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015 The Promise Long Acting Formulations Have been used to improve
More informationLetter of Amendment # 3 to:
Letter of Amendment # 3 to: HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationContraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016
Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016 Disclosure I am a Nexplanon trainer for Merck. Objectives Understand how obesity may affect pharmacokinetics
More informationBirth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy
Birth Control- an Overview Keith Merritt, MD Basics Remember, all methods of birth control are safer and have fewer side effects than pregnancy Even with perfect use, each method of birth control has a
More informationContraceptives. Kim Dawson October 2010
Contraceptives Kim Dawson October 2010 Objectives: You will learn about: The about the different methods of birth control. How to use each method of birth control. Emergency contraception What are they?
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationThe Prevention Landscape for Women: Yesterday, Today and Tomorrow. Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018
The Prevention Landscape for Women: Yesterday, Today and Tomorrow Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018 Despite global progress in the last decade, women still bear a
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationGlobal Contraception
Video Companion Guide Global Contraception Learning Objectives: By the end of the session, learners will be able to: Describe of all contraceptive methods. Develop a basic understanding of patient-centered
More informationClarification Memo # 1 to:
Clarification Memo # 1 to: HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV- Uninfected
More informationTarget Product Profiles for Drug-Drug and Drug-Device MPT Products. Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network
Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network November 3, 2011 Genesis of the Drug-Drug/Drug Device Working Group May 5,
More information11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama
HIV Preexposure Prophylaxis: Pills, Rings, Injectables, and Gels Oh My! Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 10/17/16 Financial
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationTarget Product Profiles for Drug-Drug and Drug-Device MPT Products
Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network January 10, 2012 Genesis of the Drug-Drug/Drug Device Working Group May 5,
More informationReviewer No.2 Commentary: contraceptive medicines: does choice make a difference?
Reviewer No.2 Commentary: contraceptive medicines: does choice make a difference? The detailed review by Andrew Gray and colleagues (Systematic review of contraceptive medicines: does choice make a difference?
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationExpanding access to injectable contraceptives
Expanding access to injectable contraceptives Background Catherine d'arcangues World Health Organization Geneva, 15 June 2009 06_PVL_TURIN_APRIL1 Contraceptive prevalence by method: world and development
More informationCONTINUED LESSONS FROM VOICE
CONTINUED LESSONS FROM VOICE Z Mike Chirenje MD FRCOG University of Zimbabwe, Dept. of Obstetrics and Gynaecology, College of Health Science, Harare, Zimbabwe VOICE Study Summary VOICE was a RCT (N=5029)
More information2/4/2011. What is your specialty? A. Family practice B. Internal medicine and subs C. OB/GYN D. Peds E. Surgery and subs
Steve P. Buchanan D.O. FACOOG(Dist.) TOMA Mid Winter February 11, 2011 Dallas,TX Associate Professor OB/GYN UNTHSC/TCOM 1987- present Executive Vice President, American College of Osteopathic Obstetricians
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More informationImplants and ART: weighing the evidence to guide programs
Implants and ART: weighing the evidence to guide programs Presented by: Jennifer Mason, MPH; Tabitha Sripipitana, MPH; and Sarah Yeiser, MPH Office of Population & Reproductive Health, USAID Office of
More informationPercentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015
TABLE 1 Percentage of family planning, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and Clinic characteristics 2010 Yes No Focuses on reproductive
More informationNCHA and NIU Data Dashboards 2011, 2013, 2015 Sexual Health. Evelyn Comber January 31, 2017
NCHA and NIU Data Dashboards 2011, 2013, 2015 Sexual Health Evelyn Comber January 31, 2017 NIU Male Participants and Female Participants Report Health Exam Behaviors Regardless of gender, a majority of
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationREGULATORY PATHWAYS AND CLINICAL TRIAL DESIGN FOR LONG-ACTING PrEP
REGULATORY PATHWAYS AND CLINICAL TRIAL DESIGN FOR LONG-ACTING PrEP PERSPECTIVES FROM A THEMATIC ROUNDTABLE ORGANIZED BY THE IAS INDUSTRY LIAISON FORUM BACKGROUND Since the first Phase III trials eight
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationContraception for Women and Couples with HIV. Knowledge Test
Contraception for Women and Couples with HIV Knowledge Test Instructions: For each question below, check/tick all responses that apply. 1. Which statements accurately describe the impact of HIV/AIDS in
More informationWhat do we know about HIV trial design for adolescents?
What do we know about HIV trial design for adolescents? Sinéad Delany-Moretlwe, MBBCh PhD, DTM&H International Workshop on HIV & Adolescence, Cape Town, October 2018 Outline Why include adolescents in
More informationClinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org PRE-EXPOSURE PROPHYLAXIS Speaker: Antonia Urbina, MD 9/6/2017 Pre-Exposure Prophylaxis [video transcript] 1 00:00:07,480 --> 00:00:09,139 I mean we're
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGetting to Zero in San Francisco Consortium. Zero new HIV infections Zero HIV deaths Zero stigma and discrimination
Getting to Zero in San Francisco Consortium Zero new HIV infections Zero HIV deaths Zero stigma and discrimination Agenda 1. Welcome 2. Policy Updates 3. SF HIV Epidemiology Data 4. Presentation, Panel
More informationYoung Mothers: From pregnancy to early motherhood in adolescents with HIV
Young Mothers: From pregnancy to early motherhood in adolescents with HIV Lisa L. Abuogi, MD, MSc Assistant Professor University of Colorado, Denver 8 th HIV and Women Workshop March 2, 2018 Boston, MA
More information11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities
Moving Beyond Truvada: The (Current) Future Pipeline for PrEP Raphael J. Landovitz, MD MSc Associate Professor of Medicine UCLA Center for Clinical AIDS Research & Education November 18, 2016 2 Million
More informationPrevenção do HIV e o papel dos inibidores da integrasse
Prevenção do HIV e o papel dos inibidores da integrasse Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 22 Agosto 2018 DISCLOSURES I have received a research grant from
More informationHIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS. (Part Two) Presented live August 14, 2018
HIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part Two) Presented live August 14, 2018 Welcome Back! Technical Support 800-263-6317 Mary McCarty-Arias, M.A.,
More informationBirth Control Options Chart
Hormonal Methods Birth control pills also known as mini-pills 91-99% A daily pill containing hormones that stops you from ovulating. There are combination estrogen or progestin-only (mini-pill) options.
More informationFIGO and Prevention of Unsafe Abortion LARC and PM for PAC
FIGO and Prevention of Unsafe Abortion LARC and PM for PAC Dr. Anibal Faundes Second Regional Francophone West Africa PAC Meeting: Strengthening Postabortion Family Planning Saly, Senegal, October 6-11,
More informationFamily Planning and Infertility
Family Planning and Infertility Chapter 20 Objectives Discuss types of reversible contraception Natural methods Mechanical barrier methods Hormonal contraceptives Discuss types of permanent contraception
More informationMultipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health
Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health Session Objectives This session is designed to help you: Define multipurpose prevention technologies (MPTs) Describe 3 benefits
More informationClick to edit Master title style. Unintended Pregnancy: Prevalence. Unintended Pregnancy: Risk Groups. Unintended Pregnancy: Consequences 9/23/2015
The Role of Childhood Violence, Self-esteem and Depressive Symptoms on Inconsistent Contraception Use among Young, Sexually Active Women Deborah B. Nelson, PhD Associate Professor Unintended Pregnancy:
More informationPower Point Use in EBPs. CAPP & PREP Learning Community May 15, 2018
Power Point Use in EBPs CAPP & PREP Learning Community May 15, 2018 Objectives Best practices for power point use Why use power point for EBP delivery Examples: the Good, the Bad and the Ugly Recommendations
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationLong Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint
Long Acting HIV Drugs for Prevention: what are the data? Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint DISCLOSURES I have received a research grant from Gilead Sciences
More informationPOLICY & PROCEDURE DEFINITIONS: N/A POLICY:
POLICY & PROCEDURE TITLE: Fertility Regulation Family Planning Scope/Purpose: To offer a wide range of approved methods for Family Planning services Division/Department: : All HealthPoint Clinics Policy/Procedure
More informationResponse to HIV LOGISTICAL AND OTHER PERSPECTIVES
Response to HIV LOGISTICAL AND OTHER PERSPECTIVES Margaret Brandeau Department of Management Science and Engineering Department of Medicine Stanford University Topics HIV: A humanitarian crisis Planning
More informationIAPAC Summit Daily And Intermittent PrEP
IAPAC Summit 2012 Daily And Intermittent PrEP Six Clinical Trial Sites Nyanga District Population: 500 000 Unemployment: 70% Shack dwelling 50% Background The Global iprex Study Design Double blind,
More informationContraception and birth control
Contraception and birth control Ernesto F. L. Amaral October 3 8, 2018 Population and Society (SOCI 312) Outline Introduction Brief history of fertility control Current patterns of fertility control Methods
More informationNURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS
Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide
More informationHormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence
Hormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence CHELSEA B. POLIS, PHD SEPTEMBER 16, 2016 AVAC WEBINAR GUTTMACHER INSTITUTE 2016 Acknowledgements
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationDisclosures. Objectives. Case: Anna. Case: Carla. Case: Beth. Contraception (for the Family Physician) 5/22/2015. Valary Gass, MD.
Contraception (for the Family Physician) Disclosures None Valary Gass, MD For Family Medicine Update June 2015 Objectives Help a patient choose a contraceptive that fits her life Consider co-morbidities
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationWHAT ARE CONTRACEPTIVES?
CONTRACEPTION WHAT ARE CONTRACEPTIVES? Methods used to prevent fertilization *Also referred to as birth control methods With contraceptives, it is important to look at what works for you and your body.
More informationContraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine
Contraception Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine Disclosures No financial relationships to disclose I have no commercial, financial, research ties to
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationSexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012
Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3
More informationHormonal contraception and HIV disease progression: a multi country analysis of the
Hormonal contraception and HIV disease progression: a multi country analysis of the MTCT Plus cohort Stringer EM, Sinkala MS, Giganti MG, Carter R, Toro P, El Sadr W, Stringer JSA, Abrams E Hormonal Contraception
More informationFamily Planning and Sexually Transmitted. Infections, including HIV
Infections, including HIV Family Planning and Sexually Transmitted Introduction To protect themselves, people need correct information about sexually transmitted infections (STIs), including HIV. Women
More informationThe Role of TAF in PrEP. Dr. Garrett has nothing to disclose
The Role of TAF in PrEP KATY GARRETT, PHARMD UNIVERSITY OF NORTH CAROLINA Dr. Garrett has nothing to disclose Outline PrEP Efficacy Adherence among populations Pharmacokinetic and pharmacodynamics relationship
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationPharmacology Lessons from Chemoprophylaxis Studies. Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK
Pharmacology Lessons from Chemoprophylaxis Studies Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK Pre tenofovir generation 1996-2009 PK did not inform trials
More information100% Highly effective No cost No side effects
effective? Advantages Disadvantages How do I get Cost Abstinence For some it can mean no sexual contact. For others it is no sexual intercourse or vaginal penetration. A permanent surgical procedure available
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPeople left behind: Sex workers
GAP Report 2014 People left behind: Sex workers Link with the pdf, Sex workers I am a sex worker. I face these issues. HIV prevalence among sex workers, 2009 2013 Source: Global AIDS Response Progress
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationContraceptives: Technologies and Global Markets
A BCC Research Healthcare Report HLC085A Use this report to: Learn how shifting demographic and sociological factors such as population growth, proportion of young population, and perceptions about family
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationBirth Control in Patients with Congenital Heart Disease
Birth Control in Patients with Congenital Heart Disease Arwa Saidi MB. BCh. MEd. FACC University of Florida Departments of Pediatrics and Internal Medicine Gainesville, FL There are an increasing number
More informationProgress against the HIV Epidemic: is the end in sight?
Progress against the HIV Epidemic: is the end in sight? Christine Hughes, BscPharm, PharmD, FCSHP Professor, Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Clinical Pharmacist, Northern
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationAdherence-enhancing intervention in PrEP in low-resource settings
Adherence-enhancing intervention in PrEP in low-resource settings Collaboration project: Bill and Melinda Gates Foundation project team Terrence F. Blaschke, Papa Salif Sow Kenya project team, LVCT Health
More informationIntegration of Contraceptive Counseling into HIV Services for Youth:
Integration of Contraceptive Counseling into HIV Services for Youth: Findings and Future Directions Donna McCarraher, FHI Outline I. Brief overview of integration research in clinical settings II. YouthNet
More informationIN-SITU FORMING IMPLANT SYSTEM FOR LONG ACTING HIV PROPHYLAXIS
IN-SITU FORMING IMPLANT SYSTEM FOR LONG ACTING HIV PROPHYLAXIS Shelby L. Hudson, MS PharmD Candidate UNC Eshelman School of Pharmacy November 17, 21 Research mentor: Soumya Rahima Benhabbour, PhD Date
More informationContraception update. Gina M. Brown, M.D.
Contraception update Gina M. Brown, M.D. IUDs cannot be used in HIV + women Women with thromboembolic disease can never use hormonal contraception Combined hormonal contraception increases blood pressure
More informationContraception update. Gina M. Brown, M.D.
Contraception update Gina M. Brown, M.D. IUDs cannot be used in HIV + women Women with thromboembolic disease can never use hormonal contraception Combined hormonal contraception increases blood pressure
More informationCONTRACEPTION IN HIV INFECTION DR JYOTI DHAR LEICESTER UK
CONTRACEPTION IN HIV INFECTION DR JYOTI DHAR LEICESTER UK Global figures Women account for 51.6% of HIV globally (15.9m of 30.8m HIV+ adults) UNAIDS report on the global AIDS epidemic, 2010 Estimated no.
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationWelcome and State of the Network. Cape Town, South Africa 27 th September 2016
Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living
More informationDoes your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research
Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research Objectives By the end of the session, participants will be able to: Recognize
More informationThe Role of Individual and Relationship Factors on Contraceptive Use among At-Risk Young Adults
The Role of Individual and Relationship Factors on Contraceptive Use among At-Risk Young Adults Lisa Oakley, PhD MPH 1 Marie Harvey, DrPH MPH 1 Isaac Washburn, PhD 2 April 1, 2016 Society of Behavioral
More informationBIRTH CONTROL METHOD COMPARISON CHART
BIRTH CONTROL METHOD COMPARISON CHART Abstinence 100% Yes Male latex condom 86%-95% Can increase to 98% by using with a contraceptive jelly Yes Highly effective No side effects, as with other methods No
More informationMeeting Unmet Need and Increasing Contraceptive Options and Services with Postpartum Family Planning
Meeting Unmet Need and Increasing Contraceptive Options and Services with Postpartum Family Planning Roy Jacobstein, MD, MPH EngenderHealth FIGO panel, Post-partum contraception with a focus on post-partum
More informationPrEP adherence in Black MSM in HPTN 073 and Beyond
PrEP adherence in Black MSM in HPTN 073 and Beyond Steven Shoptaw PhD { University of California Los Angeles June 24, 2014 With updates on HPTN 069 and HPTN 077 Overview Brief Epi PrEP rationale HPTN 073
More informationHEALTH. Sexual and Reproductive Health (SRH)
HEALTH The changes in global population health over the last two decades are striking in two ways in the dramatic aggregate shifts in the composition of the global health burden towards non-communicable
More informationData inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov
Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Vaccine & Infectious Disease Division Fred Hutchinson Cancer Research Center Dynamic model integration The
More informationPrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.
PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking
More informationKeywords: family planning, commodities, replacement-level fertility, ethiopia. GJHSS-H Classification: FOR Code:
Global Journal of HUMANSOCIAL SCIENCE: H Interdisciplinary Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN:
More information